Wedbush Expects Lower Earnings for Werewolf Therapeutics

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Equities researchers at Wedbush decreased their FY2025 earnings estimates for shares of Werewolf Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($1.84) per share for the year, down from their previous forecast of ($0.97). Wedbush has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics’ FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($0.63) EPS.

A number of other research firms have also recently weighed in on HOWL. JMP Securities dropped their price target on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $1.20 on Monday. The stock has a market capitalization of $53.79 million, a PE ratio of -0.78 and a beta of 0.37. Werewolf Therapeutics has a 52 week low of $1.03 and a 52 week high of $6.89. The stock has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.80. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. D. E. Shaw & Co. Inc. bought a new stake in Werewolf Therapeutics in the fourth quarter valued at approximately $26,000. XTX Topco Ltd bought a new stake in Werewolf Therapeutics during the third quarter valued at $45,000. Regal Investment Advisors LLC boosted its position in Werewolf Therapeutics by 88.1% during the fourth quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock valued at $40,000 after acquiring an additional 12,745 shares during the last quarter. Levin Capital Strategies L.P. acquired a new stake in Werewolf Therapeutics during the 4th quarter worth about $74,000. Finally, Jane Street Group LLC raised its position in shares of Werewolf Therapeutics by 261.2% in the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock worth $81,000 after acquiring an additional 39,564 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.